Race Oncology Ltd has released a press release.
Race supports Study of Extramedullary AML
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Racura Oncology
- Race Oncology tabs drug industry veteran Damian Clarke-Bruce as company’s new Managing Director/CEO
- Race Appoints Damian Clarke-Bruce as CEO & Managing Director
- Positive Pre-IND Guidance from FDA on Zantrene
- Response to ASX Price Query
- Race Develops Improved IV Formulation of Zantrene
Later from Racura Oncology
- Race Receives Cardioprotection Ethics Trial Approval
- New Collaboration to Understand Zantrene Cardioprotection
- Race Executes Contracts to Commence Breast Cancer Trial
- Pause in Trading
- Race Leadership Changes
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology